Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 185 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Emtricitabine 200 MG Clear all
Completed Phase 2 Interventional Results available

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects

NCT00654147
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir & Lopinavir/ritonavir, Raltegravir and emtricitabine/tenofovir
Drug
Lead sponsor
Margaret A. Fischl, M.D.
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2015 · Synced Sep 26, 2026, 2:58 PM EDT
Not listed No phase listed Observational

Bictegravir in the Elderly Living With HIV (BICEP)

NCT05064020
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 26, 2026, 2:58 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)

NCT00924898
View directory record Official record
Conditions
Acute HIV Infection, HIV Infections
Interventions
efavirenz, emtricitabine, and tenofovir
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 26, 2026, 2:58 PM EDT
Completed Phase 4 Interventional

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

NCT04388904
View directory record Official record
Conditions
HIV-1-infection
Interventions
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)
Drug
Lead sponsor
The Crofoot Research Center, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Sep 26, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 26, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

NCT04006704
View directory record Official record
Conditions
HIV-1
Interventions
D/C/F/TAF FDC placebo
Drug
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
6 Years to 11 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 26, 2026, 2:58 PM EDT
Completed Phase 4 Interventional Results available

Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis

NCT00108862
View directory record Official record
Conditions
HIV Infection, Tuberculosis
Interventions
Strategy: Immediate ART, Strategy: Deferred ART
Other
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
13 Years and older
Enrollment
809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 26, 2026, 2:58 PM EDT
Withdrawn Phase 3 Interventional

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

NCT01605084
View directory record Official record
Conditions
HIV
Interventions
Atazanavir, Darunavir, Ritonavir, Optimized NRTI backbone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 26, 2026, 2:58 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

NCT07708727
View directory record Official record
Conditions
HIV-1-infection
Interventions
GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
9
States / cities
Florida City, Florida • Ft. Pierce, Florida • West Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 26, 2026, 2:58 PM EDT
Completed Phase 3 Interventional

Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects

NCT00043966
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Tenofovir DF, Emtricitabine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
29
States / cities
Phoenix, Arizona • Beverly Hills, California • Fountain Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2006 · Synced Sep 26, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

NCT01095796
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Stribild, Atripla, Stribild Placebo, Atripla Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
97
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Sep 26, 2026, 2:58 PM EDT
Completed Early Phase 1 Interventional

Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV

NCT04820933
View directory record Official record
Conditions
HIV I Infection, Cardiovascular Risk Factor, Lipid Metabolism Disorders
Interventions
Doravirine 100 Mg
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 26, 2026, 2:58 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

NCT06333808
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
51
States / cities
Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 26, 2026, 2:58 PM EDT
Completed Phase 4 Interventional

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

NCT00224445
View directory record Official record
Conditions
HIV Infections
Interventions
Truvada, Atazanavir, Ritonavir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Foster City, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Sep 26, 2026, 2:58 PM EDT
Completed Phase 4 Interventional

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients

NCT00677300
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir, Darunavir, Ritonavir, Tenofovir/Emtricitabine
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2014 · Synced Sep 26, 2026, 2:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Nursing Involvement on Implementation of HIV Prevention Services

NCT05095818
View directory record Official record
Conditions
Pre-Exposure Prophylaxis (PrEP)
Interventions
PrEP-RN
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 26, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

NCT02345226
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/RPV/TAF, EFV/FTC/TDF Placebo, EFV/FTC/TDF, FTC/RPV/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
79
States / cities
Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Sep 26, 2026, 2:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs

NCT00016718
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine (ddI), Efavirenz (EFV), Emtricitabine (FTC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
90 Days to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
16
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 26, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

NCT02071082
View directory record Official record
Conditions
HIV, HBV
Interventions
E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
21
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 26, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men

NCT00856323
View directory record Official record
Conditions
Amphetamine-Related Disorders, HIV, HIV Infections
Interventions
Truvada, CM
Drug · Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Sep 26, 2026, 2:58 PM EDT
Terminated Not applicable Interventional Results available

Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals

NCT01293123
View directory record Official record
Conditions
HIV
Interventions
Raltegravir, Efavirenz
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Sep 26, 2026, 2:58 PM EDT
Not listed Phase 4 Interventional

Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age

NCT05147740
View directory record Official record
Conditions
HIV-1-infection
Interventions
B/F/TAF
Drug
Lead sponsor
Tulika Singh, MD
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palm Springs, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Sep 26, 2026, 2:58 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen

NCT02285114
View directory record Official record
Conditions
HIV-1
Interventions
F/TAF, 3rd ARV agent, Boosted PIs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
1 Month to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 26, 2026, 2:58 PM EDT
Active, not recruiting Phase 4 Interventional

Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection

NCT02656511
View directory record Official record
Conditions
HIV
Interventions
Dolutegravir, Emtricitabine/Tenofovir
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 26, 2026, 2:58 PM EDT